Compare Stocks: ATXS, ABCL, BEAM, and KOD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.38 +3.7%	$6.65	$2.74 ▼ $11.50	$3.49B	1.2	8.99 million shs	12.33 million shs
ATXS Astria Therapeutics	$12.58 +0.6%	$12.68	$3.69 ▼ $13.29	$718.13M	0.01	1.01 million shs	3.20 million shs
BEAM Beam Therapeutics	$26.75 +0.9%	$30.26	$15.60 ▼ $38.26	$2.76B	2.23	1.76 million shs	1.23 million shs
KOD Kodiak Sciences	$41.35 +3.4%	$39.10	$8.29 ▼ $47.84	$2.59B	2.21	539,418 shs	747,146 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+64.21%	+84.74%	+178.24%	+148.69%
ATXS Astria Therapeutics	0.00%	0.00%	0.00%	0.00%	+83.11%
BEAM Beam Therapeutics	0.00%	-2.66%	-5.78%	-4.22%	+52.68%
KOD Kodiak Sciences	0.00%	-8.86%	+0.24%	+11.70%	+379.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.38 +3.7%	$6.65	$2.74 ▼ $11.50	$3.49B	1.2	8.99 million shs	12.33 million shs
ATXS Astria Therapeutics	$12.58 +0.6%	$12.68	$3.69 ▼ $13.29	$718.13M	0.01	1.01 million shs	3.20 million shs
BEAM Beam Therapeutics	$26.75 +0.9%	$30.26	$15.60 ▼ $38.26	$2.76B	2.23	1.76 million shs	1.23 million shs
KOD Kodiak Sciences	$41.35 +3.4%	$39.10	$8.29 ▼ $47.84	$2.59B	2.21	539,418 shs	747,146 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+64.21%	+84.74%	+178.24%	+148.69%
ATXS Astria Therapeutics	0.00%	0.00%	0.00%	0.00%	+83.11%
BEAM Beam Therapeutics	0.00%	-2.66%	-5.78%	-4.22%	+52.68%
KOD Kodiak Sciences	0.00%	-8.86%	+0.24%	+11.70%	+379.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	12.77% Upside
ATXS Astria Therapeutics	2.00	Hold	$24.20	92.37% Upside
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	83.18% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$48.14	16.43% Upside

Current Analyst Ratings Breakdown

Latest ATXS, ABCL, BEAM, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/3/2026	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $66.00
7/17/2026	ABCL AbCellera Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	KOD Kodiak Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$47.00
7/7/2026	ABCL AbCellera Biologics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$11.00
7/7/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	46.44	N/A	N/A	$2.92 per share	3.90
ATXS Astria Therapeutics	$706K	1,017.18	N/A	N/A	$3.97 per share	3.17
BEAM Beam Therapeutics	$139.74M	19.77	N/A	N/A	$10.34 per share	2.59
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	N/A
ATXS Astria Therapeutics	-$94.26M	-$2.14	N/A	N/A	N/A	N/A	-68.81%	-41.12%	N/A
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-247.63%	-82.91%	N/A

Latest ATXS, ABCL, BEAM, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
ATXS Astria Therapeutics	N/A	10.78	10.78
BEAM Beam Therapeutics	0.09	14.57	14.57
KOD Kodiak Sciences	N/A	3.54	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ATXS Astria Therapeutics	98.98%
BEAM Beam Therapeutics	99.68%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
ATXS Astria Therapeutics	4.50%
BEAM Beam Therapeutics	3.80%
KOD Kodiak Sciences	44.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
ATXS Astria Therapeutics	30	57.09 million	54.52 million	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
KOD Kodiak Sciences	90	62.58 million	34.79 million	Optionable

ATXS, ABCL, BEAM, and KOD Headlines

Recent News About These Companies

California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD

August 15 at 3:36 AM | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Rating Lowered to Sell at Wall Street Zen

August 15 at 1:43 AM | americanbankingnews.com

Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell

August 15 at 1:41 AM | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?

August 14 at 11:39 AM | marketbeat.com

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

August 14 at 11:15 AM | zacks.com

Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 13 at 7:55 PM | marketbeat.com

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

August 13 at 4:00 PM | prnewswire.com

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Kalaris Therapeutics (KLRS)

August 13 at 1:28 PM | theglobeandmail.com

Kodiak Sciences enrols first patient in global phase 3 ALTO clinical trial of KSI-501 in patients with diabetic macular edema

August 12, 2026 | pharmabiz.comP

Kodiak Sciences Inc.: Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

August 11, 2026 | finanznachrichten.de

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

August 11, 2026 | zacks.com

Kodiak Sciences (KOD) Expected to Announce Quarterly Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

Kodiak Sciences Says First Patients Enrolled in Late-Stage Diabetic Eye Disease Trial

August 10, 2026 | finance.yahoo.com

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

August 10, 2026 | prnewswire.com

Kodiak Sciences completes enrollment in phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation

August 8, 2026 | pharmabiz.comP

The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD

August 7, 2026 | marketbeat.com

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical ...

August 6, 2026 | finance.yahoo.com

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

August 6, 2026 | prnewswire.com

Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday

August 5, 2026 | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

August 5, 2026 | americanbankingnews.com

Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $66.00 at JPMorgan Chase & Co.

August 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXS, ABCL, BEAM, and KOD Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$11.38 +0.41 (+3.74%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$11.40 +0.02 (+0.18%)

As of 08/14/2026 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Astria Therapeutics NASDAQ:ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$26.75 +0.24 (+0.91%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$26.85 +0.10 (+0.37%)

As of 08/14/2026 07:59 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Kodiak Sciences NASDAQ:KOD

$41.35 +1.37 (+3.43%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$41.40 +0.05 (+0.12%)

As of 08/14/2026 07:34 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXS, ABCL, BEAM, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXS, ABCL, BEAM, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXS, ABCL, BEAM, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXS, ABCL, BEAM, and KOD Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Astria Therapeutics NASDAQ:ATXS

Beam Therapeutics NASDAQ:BEAM

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXS, ABCL, BEAM, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXS, ABCL, BEAM, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXS, ABCL, BEAM, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXS, ABCL, BEAM, and KOD Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Astria Therapeutics NASDAQ:ATXS

Beam Therapeutics NASDAQ:BEAM

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools